<DOC>
	<DOCNO>NCT02181738</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Nivolumab previously treat ( cohort , A , B &amp; C ) newly diagnose ( cohort D ) classical Hodgkin Lymphoma subject .</brief_summary>
	<brief_title>Study Nivolumab Patients With Classical Hodgkin 's Lymphoma ( Registrational )</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Must receive prior highdose condition chemotherapy follow autologous stem cell transplant ( ASCT ) part salvage therapy cHL ( cohort A , B &amp; C enrolment close ) Subjects may Brentuximab vedotin naïve , may prior Brentuximab vedotin treatment ( cohort A , B &amp; C enrolment close ) Newly diagnose previously untreated classical Hodgkin Lymphoma ( cohort D ) Known central nervous system lymphoma Subjects nodular lymphocytepredominant Hodgkin Lymphoma Prior allogeneic stem cell transplantation ( SCT ) Chest radiation ≤ 24 week prior first dose Carmustine ≥ 600 mg/m² receive part pretransplant conditioning regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>